MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi 
Eledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
Initial data from open label Phase 2a study expected in late 2022IRVINE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Eledon...
PetMeds® Hires Pet-Industry Veteran into Pivotal Leadership Role
In her new role as VP of Product Management, Carolyn Carden will scale PetMeds’ product portfolio, including its rapidly growing...
BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales
Veteran Medical Device Industry Sales and Marketing Executive Has Over 20 Years of ExperienceBURLINGTON, Mass. and JERUSALEM, May 09, 2022...
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing...
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Oral presentations include longer term durability data from DTX301 and DTX401, and manufacturing data on the Pinnacle PCL™ (AAV vector...
Lucira Receives CE Mark for both COVID-19 & Flu and COVID-19 Molecular Tests
Lucira COVID-19 Test Packaging Lucira COVID-19 Test Packaging Lucira COVID-19 & Flu Test Packaging Lucira COVID-19 & Flu Test PackagingEMERYVILLE,...
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to...
MIMEDX Comments on Prescience Point’s False and Misleading Statements
Cautions Shareholders Not to Let Prescience Point Unravel MIMEDX’s Transformation Urges Shareholders to Protect their Investments by Voting “FOR” Dr....
Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer
Dr. Sandborn brings a wealth of clinical experience and knowledge to Ventyx as we advance our clinical-stage pipeline of novel oral...
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
World-renowned Wound Care Leaders, Terry Treadwell, MD, FACS and Brock Liden, DPM, Shared Insights on Success with AC5® Advanced Wound...
Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Adaptimmune Reports First Quarter Financial Results and Business Update
- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with...
Genenta Appoints Industry Veteran Tim Obara as Head of Business Development
Extensive experience in business development with AstraZeneca and GSKMILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta...
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results
Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase...
VectivBio to Participate at the Bank of America 2022 Healthcare Conference
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel...
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study
CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today...
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
– Cash runway extended into 2024 – – Strengthened financial position with achievement of $30 million milestone from GlaxoSmithKline and...
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody®sonelokimab...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
FDA review of NDA for FT218 continues; launch readiness preparations on-track to support potential commercial launchPresented interim results from ongoing...
Passage Bio to Report First Quarter 2022 Financial Results on May 16, 2022
PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing...